David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on X:
“Here are the phase III trials on-going for front-line mUC.
Second time Tom Powles used win on the swings and lose on the roundabouts. Team needed help with that reference.”
Ongoing Phase III trials for front-line metastatic urothelial carcinoma (mUC) focus primarily on HER2-targeted antibody-drug conjugate (ADC) combinations, FGFR3-targeted regimens, and dual immunotherapy or chemo-immunotherapy strategies following the establishment of enfortumab vedotin plus pembrolizumab (EV+P) as the standard of care.
You can also read: